<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114478">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612884</url>
  </required_header>
  <id_info>
    <org_study_id>1106005745</org_study_id>
    <nct_id>NCT01612884</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)</brief_title>
  <official_title>Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <brief_summary>
    <textblock>
      Personalized treatment approaches and antiplatelet drug choice have been proposed to
      optimize safety of coronary stenting by reducing heart attacks and repeat interventions
      while simultaneously minimizing adverse bleeding events. This study compares the efficacy of
      two laboratory guided treatment algorithms to personalize antiplatelet medication choice
      after coronary stenting
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombelastography (TEG) MA</measure>
    <time_frame>1 day</time_frame>
    <description>Persistence of high tensile clot strength measured by TEG 16-24 hours after reloading of either clopidogrel or prasugrel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic events</measure>
    <time_frame>6 months</time_frame>
    <description>Death, recurrent myocardial infarction, recurrent unstable angina, repeat coronary intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Thrombosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>TEG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel non-response defined as MAâ‰¥69 Clopidogrel response defined as MA&lt;69</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Light transmittance aggregometry</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Clopidogrel non-response defined as MPA ADP &gt;42.9% Clopidogrel response defined as MPA ADP &lt;42.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder</description>
    <arm_group_label>TEG</arm_group_label>
    <arm_group_label>Light transmittance aggregometry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder</description>
    <arm_group_label>TEG</arm_group_label>
    <arm_group_label>Light transmittance aggregometry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted with acute coronary syndrome (unstable angina, non-ST elevation
             myocardial infarction) and referred for coronary angiography.

          -  Current therapy with clopidogrel (at least 300mg loading dose, or 75mg po daily for
             &gt;5 days)

          -  Age range 21-75 years.

        Exclusion Criteria:

          -  Unable to give consent

          -  Age younger than 21 years, greater than 75 years

          -  History of stroke

          -  Body weight &lt;60 kg

          -  Acute STEMI,

          -  Thrombocytopenia&lt;100'000,

          -  requirement for chronic warfarin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eskenazi Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>June 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Rolf Kreutz</investigator_full_name>
    <investigator_title>M.D., Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
